511 related articles for article (PubMed ID: 9064988)
21. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
Borggrefe M; Haverkamp W; Shenasa M; Hindricks G; Breithardt G
J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S32-40. PubMed ID: 1279307
[TBL] [Abstract][Full Text] [Related]
22. What have clinical trials taught us about proarrhythmia?
Skanes AC; Green MS
Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
[TBL] [Abstract][Full Text] [Related]
23. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
[TBL] [Abstract][Full Text] [Related]
24. [Magnesium as an anti-arrhythmic therapy principle in supraventricular and ventricular cardiac arrhythmias].
Zehender M
Z Kardiol; 1996; 85 Suppl 6():135-45. PubMed ID: 9064958
[TBL] [Abstract][Full Text] [Related]
25. [Ischemic disorders of cardiac rhythm: effects of the autonomic nervous system on electrophysiologic findings and pharmacotherapy].
Gülker H; Thale J
Z Kardiol; 1986; 75 Suppl 5():15-34. PubMed ID: 3825228
[TBL] [Abstract][Full Text] [Related]
26. An overview of antiarrhythmic drug management of electrical storm.
Kowey PR
Can J Cardiol; 1996 Apr; 12 Suppl B():3B-8B; discussion 27B-28B. PubMed ID: 8616726
[TBL] [Abstract][Full Text] [Related]
27. Effects of amiodarone, sematilide, and sotalol on QT dispersion.
Cui G; Sen L; Sager P; Uppal P; Singh BN
Am J Cardiol; 1994 Nov; 74(9):896-900. PubMed ID: 7526675
[TBL] [Abstract][Full Text] [Related]
28. Sotalol for cardiac arrhythmias.
Med Lett Drugs Ther; 1993 Apr; 35(893):27-8. PubMed ID: 8450806
[No Abstract] [Full Text] [Related]
29. [Magnesium: current studies--critical evaluation--consequences].
Meinertz T
Z Kardiol; 1996; 85 Suppl 6():147-51. PubMed ID: 9064959
[TBL] [Abstract][Full Text] [Related]
30. Antiarrhythmic effects of growth hormone--in vivo evidence from small-animal models of acute myocardial infarction and invasive electrophysiology.
Råmunddal T; Gizurarson S; Lorentzon M; Omerovic E
J Electrocardiol; 2008; 41(2):144-51. PubMed ID: 18328337
[TBL] [Abstract][Full Text] [Related]
31. Post-infarction sustained ventricular tachycardias. The role of drugs and methods for assessing antiarrhythmic efficacy.
Campbell RW
Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():33-6. PubMed ID: 8734162
[TBL] [Abstract][Full Text] [Related]
32. Amiodarone supplants lidocaine in ACLS and CPR protocols.
Mizzi A; Tran T; Mangar D; Camporesi EM
Anesthesiol Clin; 2011 Sep; 29(3):535-45. PubMed ID: 21871409
[TBL] [Abstract][Full Text] [Related]
33. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
[TBL] [Abstract][Full Text] [Related]
34. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
Singh SN; Fletcher RD
Am J Cardiol; 1999 Nov; 84(9A):103R-108R. PubMed ID: 10568668
[TBL] [Abstract][Full Text] [Related]
35. Philosophy of antiarrhythmic approaches to ventricular tachyarrhythmias close to the 21st century.
Breithardt G; Haverkamp W; Böcker D; Borggrefe M
Rev Port Cardiol; 1998 Dec; 17(12):981-91. PubMed ID: 9973859
[TBL] [Abstract][Full Text] [Related]
36. [Therapeutic strategies in acute myocardial infarction: antiarrhythmic therapy].
Le Heuzey JY; Copie X; Iliou MC; Guize L
Arch Mal Coeur Vaiss; 1998 Apr; 91 Spec No 2():39-42. PubMed ID: 9749275
[TBL] [Abstract][Full Text] [Related]
37. Potentially significant drug interactions of class III antiarrhythmic drugs.
Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
[TBL] [Abstract][Full Text] [Related]
38. Sotalol: a new class III antiarrhythmic agent.
Zanetti LA
Clin Pharm; 1993 Dec; 12(12):883-91. PubMed ID: 8137605
[TBL] [Abstract][Full Text] [Related]
39. Class III antiarrhythmic agents in cardiac failure: lessons from clinical trials with a focus on the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA).
Doval HC
Am J Cardiol; 1999 Nov; 84(9A):109R-114R. PubMed ID: 10568669
[TBL] [Abstract][Full Text] [Related]
40. [Drug therapy of ventricular arrhythmias].
Hohnloser SH
Med Klin (Munich); 1997 Apr; 92(4):208-10. PubMed ID: 9221302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
